Leave a comment and click here to sub for MS Equity Analysis and Swing Moves.
Trevena Inc. (Nasdaq: TRVN) is set to present tomorrow February 12 at 9:15 EST at the 21st Annual BIO CEO & Investor Conference. TRVN shareholders regained some confidence in the company after a positive Type A meeting at the FDA. Bulls found additional solace in recent insider buying, and a sufficient cash reserve to get TRVN to the second quarter of 2019. Hopefully, by this time the company will have an approaching or recently passed PDUFA date accompanied by a favorable decision.
The presentation should provide guidance for executing the QT-interval study, compiling metabolite data, timelines on delivering said information, and the company’s plans and expectations for business development in 2019.
MS Money Moves and it’s Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or non-material developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.